Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) and other seizure types.
### Primary Indications
* Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome (LGS).
* Adjunctive treatment for other seizure types, particularly absence seizures, myoclonic seizures, and atonic seizures, often used when other treatments have failed.
### Adult Dosing
* **Lennox-Gastaut Syndrome (LGS):**
* Starting dose: 5 mg twice daily.
* Titration: Increase dose by 5-10 mg every week as tolerated, not to exceed 10 mg twice daily.
* Maintenance dose: Typically 10-20 mg twice daily.
* Maximum dose: 20 mg twice daily (40 mg/day).
* **Other Seizure Types:**
* Starting dose: 5 mg twice daily.
* Titration: Increase dose by 5-10 mg every week as tolerated.
* Maintenance dose: Typically 20-40 mg/day divided into two doses.
* Maximum dose: 40 mg/day divided into two doses.
### Pediatric Dosing
* **Lennox-Gastaut Syndrome (LGS):**
* **2 years and older:**
* Starting dose: 5 mg once daily.
* Titration: Increase dose by 2.5-5 mg every week as tolerated.
* Maintenance dose: Typically 0.5-1 mg/kg/day divided into two doses.
* Maximum dose: 10 mg twice daily (20 mg/day).
* **Under 2 years:** Dosing is not well-established and should be individualized with caution. The safety and efficacy have not been fully evaluated in children younger than 2 years.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. Reduced doses may be necessary. Specific recommendations vary.
* **Renal Impairment:** Use with caution. Reduced doses may be necessary, especially in severe impairment.
* **Concomitant Medications:** Consider interactions with other CNS depressants and CYP3A4 inhibitors/inducers.
### Contraindications
* Hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis.
* Severe sleep apnea.
* Acute angle-closure glaucoma.
### Adverse Effects
Common adverse effects include somnolence, decreased appetite, constipation, aggression, irritability, difficulty speaking, and ataxia. Serious adverse effects can include severe skin reactions (e.g., Stevens-Johnson syndrome), suicidal behavior or ideation, withdrawal symptoms, and respiratory depression.
### Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of sedation, respiratory depression, and coma.
* **CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** May increase clobazam plasma concentrations, increasing risk of adverse effects.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine):** May decrease clobazam plasma concentrations, potentially reducing efficacy.
* **Valproic Acid:** Coadministration may lead to increased valproic acid levels and potential toxicity.
### Monitoring
* Monitor for seizure frequency and severity.
* Assess for adverse effects, particularly somnolence, behavior changes, and signs of skin reactions.
* Monitor for signs of withdrawal upon discontinuation.
* Consider therapeutic drug monitoring for clobazam and its active metabolite, N-desmethylclobazam, especially in patients with hepatic or renal impairment or when interacting medications are used.
### Clinical Pearls
* Clobazam is a Schedule IV controlled substance.
* Dose should be individualized based on efficacy and tolerability.
* Slow titration and gradual withdrawal are essential to minimize withdrawal symptoms.
* Clobazam is generally considered to have a lower risk of cognitive impairment compared to some other benzodiazepines, but caution is still warranted.
* The active metabolite, N-desmethylclobazam (norclobazam), has a long half-life and contributes to the overall therapeutic effect and potential for accumulation.
***
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and guidelines, and use clinical judgment when making treatment decisions.*
